These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 30918432)

  • 61. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H; Wang C; Zhang Y; Wei S; Li X; Zhang Z
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novel biomarkers for the management of chronic hepatitis B.
    Inoue T; Tanaka Y
    Clin Mol Hepatol; 2020 Jul; 26(3):261-279. PubMed ID: 32536045
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.
    Hosaka T; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Aliment Pharmacol Ther; 2019 Feb; 49(4):457-471. PubMed ID: 30663078
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Nikolopoulou G; Raptopoulou-Gigi M; Gogos C; Vafiadis-Zouboulis I; Karamanolis D; Chouta A; Ilias A; Drakoulis C; Mimidis K; Ketikoglou I; Manesis E; Mela M; Hatzis G; Dalekos GN;
    J Viral Hepat; 2015 Feb; 22(2):120-7. PubMed ID: 25040685
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
    Wang ML; Liao J; Wei B; Zhang DM; He M; Tao MC; Chen EQ; Tang H
    Infect Dis (Lond); 2018 Jul; 50(7):522-530. PubMed ID: 29463147
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase.
    Lee HW; Kim EH; Lee J; Kim SU; Park JY; Kim DY; Ahn SH; Han KH; Kim BK
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00140. PubMed ID: 32352711
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.
    Liang LY; Wong VW; Toyoda H; Tse YK; Yip TC; Yuen BW; Tada T; Kumada T; Lee HW; Lui GC; Chan HL; Wong GL
    J Gastroenterol; 2020 Sep; 55(9):899-908. PubMed ID: 32556643
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Natural History of Chronic Hepatitis B Virus Infection in Ahvaz City, Iran.
    Makvandi M; Soleimani Jelodar R; Samarbafzadeh A; Neisi N; Sharifi Z; Gholampour A; Masjedizadeh A; Shayesteh A
    Asian Pac J Cancer Prev; 2018 Aug; 19(8):2125-2129. PubMed ID: 30139211
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice.
    Lin B; Ha NB; Liu A; Trinh HN; Nguyen HA; Nguyen KK; Ahmed A; Keeffe EB; Garcia RT; Garcia G; Nguyen MH
    J Gastroenterol Hepatol; 2013 May; 28(5):855-60. PubMed ID: 23278507
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection.
    Ueda N; Kawaoka T; Imamura M; Aikata H; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Hayes CN; Yokozaki M; Chayama K
    BMC Gastroenterol; 2020 Sep; 20(1):314. PubMed ID: 32977741
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma.
    Ding Y; Liu K; Xu Y; Zhao Q; Lou S; Xiang X; Yan L; Cao Z; Xie Q; Zhu C; Bao S; Wang H
    Cancer Med; 2020 May; 9(9):3057-3069. PubMed ID: 32150664
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment.
    Cheung KS; Seto WK; Wong DK; Mak LY; Lai CL; Yuen MF
    Oncotarget; 2017 Jul; 8(29):47507-47517. PubMed ID: 28537900
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Hepatitis B e antigen and the risk of hepatocellular carcinoma.
    Yang HI; Lu SN; Liaw YF; You SL; Sun CA; Wang LY; Hsiao CK; Chen PJ; Chen DS; Chen CJ;
    N Engl J Med; 2002 Jul; 347(3):168-74. PubMed ID: 12124405
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Association of Mac-2-binding protein glycosylation isomer level with nutritional status in chronic liver disease.
    Eso Y; Takai A; Taura K; Takahashi K; Ueda Y; Marusawa H; Seno H
    J Gastroenterol Hepatol; 2018 Feb; ():. PubMed ID: 29473206
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.
    Wang HW; Lai HC; Hu TH; Su WP; Lu SN; Lin CH; Hung CH; Chuang PH; Wang JH; Lee MH; Chen CH; Peng CY
    J Gastroenterol Hepatol; 2019 Feb; 34(2):442-449. PubMed ID: 29968933
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Serum HBsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection.
    Zeng DW; Liu YR; Dong J; Zhu YY; Li YB; Chen J; Zheng Q; Jiang JJ
    Mol Med Rep; 2015 May; 11(5):3465-72. PubMed ID: 25592612
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.
    Moucari R; Korevaar A; Lada O; Martinot-Peignoux M; Boyer N; Mackiewicz V; Dauvergne A; Cardoso AC; Asselah T; Nicolas-Chanoine MH; Vidaud M; Valla D; Bedossa P; Marcellin P
    J Hepatol; 2009 Jun; 50(6):1084-92. PubMed ID: 19376603
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.